Clinical Trials | May 02, 2023
Lilly's Lebrikizumab shows improved face or hand dermatitis
Lebrikizumab is an investigational high-affinity and potent IL-13 inhibitor being studied in adult and adolescent patients
Lebrikizumab is an investigational high-affinity and potent IL-13 inhibitor being studied in adult and adolescent patients
Once approved, Columvi will be the first CD20xCD3 T-cell-engaging bispecific antibody available to treat people in Europe with this aggressive lymphoma
Clinic will offer Comprehensive Genetic Counselling and Testing Services to empower patients with personalized care
The partnership will capitalize on the combined capabilities of the two organizations
This approval reflects Biocon Biologics' compliance with the highest international regulatory standards
The policymakers, doctors and, patient bodies discuss ways to implement thalassemia control programme nationally
The news on a shift in its focus comes after the refinement of Bayer’s early innovation framework
Cipla has recently signed an agreement to make and market the diabetes therapy Galvus and its combination brands in India from 01 January 2026.
The funding will be used to expand the product line for remote patient monitoring and to scale the business across Asia and Africa
Bridging the gap between histopathology and molecular pathology
Subscribe To Our Newsletter & Stay Updated
